Medical Device News Magazine

First Left Atrial Appendage Closures Performed Under Conscious Sedation with its CLAAS Technology at AF Symposium 2020

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Conformal Medical, Inc. announced today the presentation of the first left atrial appendage closure (LAAC) cases with its unique CLAAS® Technology in patients under conscious sedation without general anesthesia.

Drs. Petr Neuzil and Vivek Reddy will present “ICE-Guided Implantation of the Conformal Left Atrial Appendage Closure Device: First Clinical Report” at the AF Symposium meeting in Washington, D.C., January 23-24.

LAAC is an emerging therapy to prevent strokes in patients with atrial fibrillation (AFib). The Conformal CLAAS Implant has a unique foam-based architecture designed for simpler delivery in patients under conscious sedation utilizing fluoroscopy and Intracardiac Echo (ICE) eliminating the need for Transesophageal Echo (TEE) and obligatory general anesthesia. These first procedures using the conscious sedation protocol were successfully performed at Homolka Hospital in Prague, Czech Republic.

“The ability to use ICE imaging streamlines the LAAC procedure by providing the required imaging without the need for TEE and general anesthesia,” said Professor Neuzil, Department Head, Cardiology, Homolka Hospital. “In the eight cases we performed at Homolka Hospital, we achieved successful closure with one size device, significantly streamlining the procedures.”

Over six million people in the United States suffer from AFib, putting them at increased risk of stroke. The current standard of care for stroke prevention is chronic use of oral anticoagulants, which are not well accepted by patients due to concern about associated bleeding. The left atrial appendage (LAA) is a pouch off the upper heart chamber where clots associated with stroke in AFib patients form. LAAC with the Conformal System eliminates the need for anticoagulation and is emerging as an alternative stroke prevention strategy. The LAA sealing procedure is performed minimally invasively from a small incision in the groin.

“These results validate the ability of Conformal’s CLAAS System to successfully close the LAA without the need for TEE and general anesthesia,” said Aaron V. Kaplan, MD, Professor of Medicine at Dartmouth and Co-Founder of Conformal Medical. “The initial 27 Conformal cases to date demonstrate the ability of Conformal’s two sizes to address a wide spectrum of LAA anatomies, which would have required 5-8 sizes with other devices. The Conformal System has the potential to make the LAAC procedure simpler to perform and more accessible to AFib patients at risk of stroke.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”